pathophysiology 12 Molecular genetics overview

By: itskind alike

Go here to read the rest:
pathophysiology 12 Molecular genetics overview - Video

Recommendation and review posted by Bethany Smith

Definitions of Genetics

By: Rafae Lexi

Read more:
Definitions of Genetics - Video

Recommendation and review posted by Bethany Smith

Carmichael C (2013): Leukaemia genetics
Walter and Eliza Hall Institute Postgraduate lecture 6 May 2013 Dr Catherine Carmichael Postdoctoral Fellow, Kile Laboratory Walter and Eliza Hall Institute.

By: WalterandElizaHall

Read more:
Carmichael C (2013): Leukaemia genetics - Video

Recommendation and review posted by Bethany Smith

Genetics - Mendelian 1 of 2
Genetics - Mendelian 1 of 2.

By: T. Heath Ogden

See original here:
Genetics - Mendelian 1 of 2 - Video

Recommendation and review posted by Bethany Smith

Genetics Smart Test 8 , best book for NEET
Napellus Edutech #39;s Biology Smart Test Demos.

By: NEET

Continue reading here:
Genetics Smart Test 8 , best book for NEET - Video

Recommendation and review posted by Bethany Smith

lyrics- Genetics Rap
here is the lyric video.

By: Cindy Lay

Go here to see the original:
lyrics- Genetics Rap - Video

Recommendation and review posted by Bethany Smith

Laflamme Genetics mystery
Using science and genetics to determine rightful parents.

By: Penoblafs

Here is the original post:
Laflamme Genetics mystery - Video

Recommendation and review posted by Bethany Smith

AMEND Patient Information Day 2013 - Dr Louise Izatt - Genetics Department Role in Talking with Kids
Dr Louise Izatt (Guy #39;s St Thomas #39;s, London) provides an insight into the work of the Genetics Department in relation to multiple endocrine neoplasia and he...

By: Jo Grey

Read the rest here:
AMEND Patient Information Day 2013 - Dr Louise Izatt - Genetics Department Role in Talking with Kids - Video

Recommendation and review posted by Bethany Smith

All Out Warfare at Apex Genetics
Normally I won #39;t upload videos this long but this fight on Apex Genetics was so intense I decided to just do the whole thing.

By: zoid34

See more here:
All Out Warfare at Apex Genetics - Video

Recommendation and review posted by Bethany Smith

Wah, Wah, Wah: You Have Better Genetics - BBOD #196
Wah, Wah, Wah: You Have Better Genetics - BBOD #196 Need help? Ask me questions here... http://bit.ly/X9cJjR.

By: BeardedBeastofDuloc

Read more here:
Wah, Wah, Wah: You Have Better Genetics - BBOD #196 - Video

Recommendation and review posted by Bethany Smith

Alta Genetics Artificial Insemination Instructional Video
Learn about reproductive anatomy, breeding, heat detection and semen handling techniques, AI Equipment and Key Performance Indicators for reproduction.

By: Alta Genetics

Continued here:
Alta Genetics Artificial Insemination Instructional Video - Video

Recommendation and review posted by Bethany Smith

5) Indicador de Eficiencia Reproductivo

By: Alta Genetics

Link:
5) Indicador de Eficiencia Reproductivo - Video

Recommendation and review posted by Bethany Smith

Cuffin Like A Russian (OFFICIAL) - Dj FarrOut - Team Irish Yardies
Cuffin Like A Russian (OFFICIAL) - Dj FarrOut - Team Irish Yardies FOLLOW MI GENERAL...@GENERAL_KOJAK AND @TEAMIRISHYARDIE , @YOUNG_OISIN , @DJFARROUT PON TW...

By: MCThornCity

See the rest here:
Cuffin Like A Russian (OFFICIAL) - Dj FarrOut - Team Irish Yardies - Video

Recommendation and review posted by Bethany Smith

CHICAGO--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today highlighted ongoing clinical development programs for ADCETRIS (brentuximab vedotin) in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress with collaborator antibody-drug conjugate (ADC) programs that were presented at the 49th Annual Meeting of the American Society of Clinical Oncology being held May 31 June 4, 2013, in Chicago, IL. The phase 3 clinical trials, called ECHELON-1 and ECHELON-2, are evaluating ADCETRIS for the frontline treatment of HL and MTCL, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphoma. ADCETRIS is an ADC directed to CD30, a defining marker of HL and sALCL, which was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL. In addition, encouraging phase 1 data were presented from two ADC clinical programs being developed by Genentech, a member of the Roche Group (RO.SW) (SWX:ROG)(RHHBY), using Seattle Genetics technology.

ADCs represent an innovative and growing field in the fight against cancer, which is evident by the interest in this therapeutic approach at the ASCO annual meeting, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. As the first ADC to be approved by the FDA in this new class, we are focused on broadening the evaluation of ADCETRIS in earlier lines of therapy with our ongoing ECHELON-1 and ECHELON-2 global phase 3 trials, which are designed to redefine the standard of care for frontline treatment of HL and MTCL. While we advance our internal programs, our collaborators are making important progress utilizing our ADC technology. Notably, Genentech is presenting encouraging phase 1 data for two ADC candidates in solid tumor settings.

Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Of the approximately 30 ADC candidates currently in development, more than half utilize Seattle Genetics proprietary ADC technology.

Phase III Trial of Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine (A+AVD) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) as Front-line Treatment for Advanced Classical Hodgkin Lymphoma (HL) (Abstract #TPS8612)

Recent phase 1 data presented at the 2012 American Society of Hematology (ASH) Annual Meeting demonstrated that A+AVD, which removes bleomycin from the standard frontline ABVD regimen, was associated with a manageable safety profile and a complete remission (CR) rate of 96 percent in the treatment of newly diagnosed HL patients. A global phase 3 study, called ECHELON-1, is an ongoing open-label, randomized, multi-center trial designed to investigate A+AVD versus ABVD as frontline therapy in patients with advanced classical HL. The primary endpoint is modified progression free survival (mPFS) per independent review facility assessment using the Revised Response Criteria for malignant lymphoma (Cheson, 2007). Secondary endpoints include overall survival (OS), CR rate and safety. The trial is being conducted in North America, Europe, Latin America and Asia. The study will enroll approximately 1,040 eligible patients (approximately 520 patients per treatment arm) who have histologically-confirmed diagnosis of Stage III or IV classical HL and who have not been previously treated with systemic chemotherapy or radiotherapy.

Phase III Trial of Brentuximab Vedotin and CHP Versus CHOP in the Frontline Treatment of Patients with CD30+ Mature T-Cell Lymphomas (MTCL) (Abstract #TPS8611)

Recent phase 1 data presented at the 2012 ASH Annual Meeting demonstrated that ADCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (A+CHP) in the frontline treatment of MTCL was associated with a manageable safety profile and 100 percent objective response rate, including 88 percent CRs. A global phase 3 study, called ECHELON-2, is an ongoing randomized, double-blind, placebo-controlled, multi-center trial designed to investigate A+CHP versus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) as frontline therapy in patients with CD30-expressing MTCL. Approximately 300 patients (approximately 150 patients per treatment arm) will be randomized to receive A+CHP or CHOP for six to eight cycles every three weeks. The primary endpoint is progression-free survival (PFS) per independent review facility assessment using the Revised Response Criteria for malignant lymphoma. Secondary endpoints include OS, CR rate and safety. The trial is being conducted in North America, Europe and Asia.

ADCETRIS is currently not approved for frontline treatment of HL and MTCL. For more information about ECHELON-1 and ECHELON-2, visit http://www.clinicaltrials.gov.

A Phase I Study of the Safety and Pharmacokinetics of DNIB0600A, an Anti-Napi2b-vc-MMAE Drug Conjugate, in Patients with Non-Small Cell Lung Cancer (NSCLC) and Platinum-Resistant Ovarian Cancer (OC) (Abstract #2507)

See original here:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and ...

Recommendation and review posted by Bethany Smith

American Fire Culture: Needs Gene Therapy
Dr. Burton A. Clark, EFO April 2013.

By: Tucker Palmatier

Continue reading here:
American Fire Culture: Needs Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Non-Viral Gene Therapy

By: Scott Swing

Continue reading here:
Non-Viral Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Gene Therapy and DNA Probes - A-Level (A2) Biology Revision
Gene Therapy and DNA Probes. A2 Biology. OCR Exam Board. Unit 5.2.3. F215. The "You need to know..." section has come from the OCR specification.

By: ocrbiologya2

Read more:
Gene Therapy and DNA Probes - A-Level (A2) Biology Revision - Video

Recommendation and review posted by Bethany Smith

HIALEAH (CBSMiami) A team of Hialeah veterinarians performed a groundbreaking medical procedure on a dog to help him walk again.

Brando, a 9-year-old German shepherd, received an innovative two-part stem cell therapy at Paradise Animal Clinic in Hialeah on Wednesday. Its the first time this type of therapy has been performed in Florida.

The dog had been paralyzed from the waist down since January and used a doggie wheelchair to get around.

Vets said that he had a skin infection that paralyzed his lungs and then spread to a disc in his back. The infection caused 80 percent of Brandos leg muscles to weaken.

We were totally emotionally destroyed. Kids were crying, wife was upset, I was upset, said owner Manuel Bouza. Obviously the issue was he was so sick whether we put him down because hes paralyzed or whether we deal with it.

Bouza said that they wanted to do whatever they could to help him. One day, he stumbled across a video on YouTube about a dog in Great Britain who had received a stem cell treatment and he became interested.

With no proven options for recovery, they decided to try an experimental stem cell procedure never performed before in Florida.

This is a last ditch effort, said Bouza.

During the procedure, surgeons took fat from Brandos stomach and processed out the stem cells which were then re-injected into his spinal cord. They hope the cells will regenerate tissue and help Brando become more mobile.

The idea is that stem cells are able to go to a given place in the body and repair, said said animal surgeon Jose Gorostiza. Hopefully they will help the cells that are there function again, the new ones.

Here is the original post:
Paralyzed Dog Receives Stem Cell Therapy

Recommendation and review posted by simmons

Discovery 13: Personalized Medicine Panel
Innovation in personalized medicine is generating new technologies that provide insights about health at the DNA level. This panel provides an industry scan ...

By: OceDiscovery

Here is the original post:
Discovery 13: Personalized Medicine Panel - Video

Recommendation and review posted by sam

Spinal cord injury L1 L2 3 months post surgery
Fractura de columna L1 y L2 3 meses despues de ciruga.

By: GetOutOfYourRoom

Read the rest here:
Spinal cord injury L1

Recommendation and review posted by sam

Call Info Medicare Coverage Handicapped Scooters Spinal Cord Injury Around Westminster
Call 1-888-982-4194 Free Hoveround Information - Insurance Accepted*

By: HoveroundChair1

See more here:
Call Info Medicare Coverage Handicapped Scooters Spinal Cord Injury Around Westminster - Video

Recommendation and review posted by sam

Discount Medicare Providers Handicapped Chairs Spinal Cord Injury By Bell
Call 1-888-982-4194 Free Hoveround Information - Insurance Accepted*

By: HoveroundChair1

Read more here:
Discount Medicare Providers Handicapped Chairs Spinal Cord Injury By Bell - Video

Recommendation and review posted by sam

Anti-doping experts reported progress Thursday in the search for a reliable test for gene doping, although they still don't know when it will be ready for use in competition.

IOC medical commission chairman Arne Ljungqvist said a test would be put into use at the Olympics and other events as soon as a method is proven reliable regardless of whether hard evidence exists that athletes are manipulating their genes to improve performance.

No such evidence exists so far, although the World Anti-Doping Agency has received information that "there is an interest out there in certain circles," particularly among coaches and other members of athletes' entourages, Ljungqvist said.

"We will certainly as soon as we have a reliable method available make use of it for the purpose of identifying whether there is something going on based on strategic information," the Swedish official said.

"I would really estimate that people realize that it's probably a bit risky today, perhaps very risky if they should jump to misuse. But there seems to be mental readiness to take it on once it is available in some sort of safe way," he said.

With tests now able to reliably detect more conventional forms of doping, gene doping is considered the potential future of cheating in sports. While it offers the potential for enhancing muscle growth and increasing strength and endurance, gene doping also carries potential risks such as serious genetic damage, including cancer.

Regulating gene and cell doping is especially complicated because the line between their use as treatment for muscle diseases and misuse for performance enhancement is blurred, said Ljungqvist, who is also a WADA vice president and chairman of its health, medical and research committee.

Signs of gene doping are also varied and subtle and can be easily confused with physiological changes resulting from diet or simple illness, said Theodore Friedmann, chairman of WADA's gene doping panel.

Still, he said experts were "cautiously optimistic, that we are making progress, and that will help sport and will help future athletes do what they do best, and that is compete in the clean world."

"So that's why I feel optimistic that we are being proactive at this stage, not reactive," Friedmann said, adding that testing remained at the laboratory stage at present.

Read the original post:
Gene doping test for athletes in the works

Recommendation and review posted by Bethany Smith

Anti-doping experts reported progress in the search for a reliable test for gene doping, although they still don't know when it will be ready for use in competition.

IOC medical commission chairman Arne Ljungqvist said a test would be put into use at the Olympics and other events as soon as a method is proven reliable - regardless of whether hard evidence exists that athletes are manipulating their genes to improve performance.

No such evidence exists so far, although the World Anti-Doping Agency has received information that "there is an interest out there in certain circles," particularly among coaches and other members of athletes' entourages, Ljungqvist said.

"We will certainly as soon as we have a reliable method available make use of it for the purpose of identifying whether there is something going on based on strategic information," the Swedish official said.

"I would really estimate that people realize that it's probably a bit risky today, perhaps very risky if they should jump to misuse. But there seems to be mental readiness to take it on once it is available in some sort of safe way," he said.

With tests now able to reliably detect more conventional forms of doping, gene doping is considered the potential future of cheating in sports. While it offers the potential for enhancing muscle growth and increasing strength and endurance, gene doping also carries potential risks such as serious genetic damage, including cancer.

Regulating gene and cell doping is especially complicated because the line between their use as treatment for muscle diseases and misuse for performance enhancement is blurred, said Ljungqvist, who is also a WADA vice president and chairman of its health, medical and research committee.

Signs of gene doping are also varied and subtle and can be easily confused with physiological changes resulting from diet or simple illness, said Theodore Friedmann, chairman of WADA's gene doping panel.

Still, he said experts were "cautiously optimistic, that we are making progress, and that will help sport and will help future athletes do what they do best, and that is compete in the clean world."

"So that's why I feel optimistic that we are being proactive at this stage, not reactive," Friedmann said, adding that testing remained at the laboratory stage at present.

Original post:
Experts make progress on gene doping tests

Recommendation and review posted by Bethany Smith

SCIENTISTS have discovered one of the genes that cause a muscle disease so harmful newborn babies rarely survive more than a few days.

The West Australian Institute for Medical Research co-ordinated the worldwide research that discovered the gene KLHL40, which is now known to cause 20 per cent of cases within a particular type of nemaline myopathy.

Researchers identified 19 mutations in the gene, which affects muscle development and function.

Babies with the gene mutation suffered severe muscle weakness, allowing little movement within the womb, bone fractures, respiratory failure and swallowing difficulties at birth.

Professor Nigel Laing said he had been searching for the gene since 1996.

"Even 17 years ago, we felt this disease was a different level of severity of nemaline myopathy so it was likely to be a different group of muscle proteins involved," he said.

"After years of work, that has turned out to be the case."

Professor Laing said he expected prenatal and pre-implantation testing would begin soon.

The paper's lead author, Gina Ravenscroft, said the research began with a WA couple whose baby died after five days and a Turkish couple who lost three babies in a row.

Researchers expanded the study to DNA samples from families in Japan, Vietnam, France, Turkey, Italy, Israel and Sweden.

Read more from the original source:
Gene behind muscle disease in babies found

Recommendation and review posted by Bethany Smith